Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile
Non Hodgkin Lymphoma
DRUG: Fludarabine Phosphate (Fludara)
Complete response rate, Measurement of outcome 4 to 6 weeks after EOT
Overall response rate, molecular response rate, toxicity profile, patients quality of life, Measurement of outcome 4 to 6 weeks after EOT
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.